CM
IMVT icon

Caption Management’s Immunovant IMVT Stock Holding History

Caption Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-107,100
Closed -$2.65M – 1767
2024
Q4 		$2.65M Sell
107,100
-187,100
-64% -$5.31M 0.03% 598
2024
Q3 		$8.39M Buy
294,200
+169,200
+135% +$4.99M 0.13% 183
2024
Q2 		$3.3M Sell
125,000
-92,500
-43% -$2.63M 0.05% 376
2024
Q1 		$7.03M Sell
217,500
-68,000
-24% -$2.48M 0.11% 235
2023
Q4 		$12M Sell
285,500
-426,500
-60% -$15.7M 0.16% 157
2023
Q3 		$27.3M Buy
712,000
+694,500
+3,969% +$15.7M 0.42% 43
2023
Q2 		$332K Hold
17,500
– – 0.01% 886
2023
Q1 		$271K Buy
+17,500
New +$304K 0.01% 890
2021
Q4 		– Sell
-185,200
Closed -$1.61M – 1748
2021
Q3 		$1.61M Hold
185,200
– – 0.02% 853
2021
Q2 		$1.96M Sell
185,200
-24,200
-12% -$338K 0.03% 681
2021
Q1 		$3.36M Buy
+209,400
New +$5.52M 0.07% 350

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caption Management's IMVT Position: Q1 2026 in Review

Caption Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 16,000 shares — an estimated $407K sold.

Caption Management first reported a position in IMVT in Q1 2021 and held it in 9 quarters. The position peaked at $3.67M in Q1 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Caption Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 16,000 Immunovant shares in Q1 2026, an estimated $407K.
  • Caption Management first reported a position in Immunovant in Q1 2021 and held it in 9 quarters.
  • Caption Management's Immunovant position peaked at $3.67M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.